High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies
Visual Abstract - <img class="highwire-fragment fragment-image" alt="Figure1" src="http://www.bloodjournal.org/content/bloodjournal/132/9/892/F1.medium.gif" width="411" height="440"/>Download figureOpen in new tabDownload powerpoint - - High-r...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
30 August 2018
|
| In: |
Blood
Year: 2018, Jahrgang: 132, Heft: 9, Pages: 892-902 |
| ISSN: | 1528-0020 |
| DOI: | 10.1182/blood-2018-01-826008 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1182/blood-2018-01-826008 Verlag, Volltext: http://www.bloodjournal.org/content/132/9/892 
|
| Verfasserangaben: | Peter Dreger, Paolo Ghia, Johannes Schetelig, Michel van Gelder, Eva Kimby, Mauricette Michallet, Carol Moreno, Tadeusz Robak, Stephan Stilgenbauer and Emili Montserrat |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1667457365 | ||
| 003 | DE-627 | ||
| 005 | 20230426071906.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190614s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/blood-2018-01-826008 |2 doi | |
| 035 | |a (DE-627)1667457365 | ||
| 035 | |a (DE-599)KXP1667457365 | ||
| 035 | |a (OCoLC)1341227918 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Dreger, Peter |e VerfasserIn |0 (DE-588)1028891881 |0 (DE-627)732699894 |0 (DE-576)376320966 |4 aut | |
| 245 | 1 | 0 | |a High-risk chronic lymphocytic leukemia in the era of pathway inhibitors |b integrating molecular and cellular therapies |c Peter Dreger, Paolo Ghia, Johannes Schetelig, Michel van Gelder, Eva Kimby, Mauricette Michallet, Carol Moreno, Tadeusz Robak, Stephan Stilgenbauer and Emili Montserrat |
| 264 | 1 | |c 30 August 2018 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 14.06.2019 | ||
| 520 | |a Visual Abstract - <img class="highwire-fragment fragment-image" alt="Figure1" src="http://www.bloodjournal.org/content/bloodjournal/132/9/892/F1.medium.gif" width="411" height="440"/>Download figureOpen in new tabDownload powerpoint - - High-risk chronic lymphocytic leukemia (CLL) has been defined by clinical and/or genetic resistance (TP53 abnormalities) to treatment with chemoimmunotherapy (CIT). With the availability of pathway inhibitors (PIs), such as kinase inhibitors and BCL2 antagonists, the outlook of CIT-resistant patients has dramatically improved. Here, we propose a revision of the concept of high-risk CLL, driven by TP53 abnormalities and response to treatment with PI. CLL high-risk-I, CIT-resistant is defined by clinically CIT-resistant disease with TP53 aberrations, but fully responsive to PI. This category is largely the domain of PI-based therapy, and cellular therapy (ie, allogeneic hematopoietic cell transplantation) remains an option only in selected patients with low individual procedure-related risk. In CLL high-risk-II, CIT- and PI-resistant, characterized by increasing exhaustion of pharmacological treatment possibilities, cellular therapies (including chimeric antigen receptor-engineered T cells) should be considered in patients eligible for these procedures. Moreover, molecular and cellular therapies are not mutually exclusive and could be used synergistically to exploit their full potential. | ||
| 773 | 0 | 8 | |i Enthalten in |t Blood |d Washington, DC : American Society of Hematology, 1946 |g 132(2018), 9, Seite 892-902 |h Online-Ressource |w (DE-627)266886647 |w (DE-600)1468538-3 |w (DE-576)075961938 |x 1528-0020 |7 nnas |a High-risk chronic lymphocytic leukemia in the era of pathway inhibitors integrating molecular and cellular therapies |
| 773 | 1 | 8 | |g volume:132 |g year:2018 |g number:9 |g pages:892-902 |g extent:11 |a High-risk chronic lymphocytic leukemia in the era of pathway inhibitors integrating molecular and cellular therapies |
| 856 | 4 | 0 | |u https://doi.org/10.1182/blood-2018-01-826008 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.bloodjournal.org/content/132/9/892 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190614 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 1028891881 |a Dreger, Peter |m 1028891881:Dreger, Peter |d 910000 |d 910100 |e 910000PD1028891881 |e 910100PD1028891881 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1667457365 |e 3487141078 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"recId":"1667457365","note":["Gesehen am 14.06.2019"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"subtitle":"integrating molecular and cellular therapies","title":"High-risk chronic lymphocytic leukemia in the era of pathway inhibitors","title_sort":"High-risk chronic lymphocytic leukemia in the era of pathway inhibitors"}],"person":[{"role":"aut","display":"Dreger, Peter","roleDisplay":"VerfasserIn","given":"Peter","family":"Dreger"}],"relHost":[{"titleAlt":[{"title":"Blood online"}],"part":{"issue":"9","pages":"892-902","year":"2018","extent":"11","volume":"132","text":"132(2018), 9, Seite 892-902"},"pubHistory":["1.1946 -"],"recId":"266886647","corporate":[{"display":"American Society of Hematology","roleDisplay":"Herausgebendes Organ","role":"isb"}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"High-risk chronic lymphocytic leukemia in the era of pathway inhibitors integrating molecular and cellular therapiesBlood","note":["Gesehen am 21.04.2023"],"title":[{"title_sort":"Blood","title":"Blood","subtitle":"journal of the American Society of Hematology"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["1528-0020"],"zdb":["1468538-3"],"eki":["266886647"]},"origin":[{"publisherPlace":"Washington, DC ; Philadelphia, Pa. ; Stanford, Calif.","dateIssuedDisp":"1946-","dateIssuedKey":"1946","publisher":"American Society of Hematology ; Saunders ; HighWire Press"}]}],"physDesc":[{"extent":"11 S."}],"id":{"doi":["10.1182/blood-2018-01-826008"],"eki":["1667457365"]},"origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"30 August 2018"}],"name":{"displayForm":["Peter Dreger, Paolo Ghia, Johannes Schetelig, Michel van Gelder, Eva Kimby, Mauricette Michallet, Carol Moreno, Tadeusz Robak, Stephan Stilgenbauer and Emili Montserrat"]}} | ||
| SRT | |a DREGERPETEHIGHRISKCH3020 | ||